摘要
目的探讨异环磷酰胺(IFO)联合卡铂(CBP)、足叶乙甙(Vp16)与环磷酰胺(CTX)联合CBP、Vp16治疗晚期肺腺癌的效果。方法应用IFO联合CBP、Vp16(IFO组)和CTX联合CBP、Vp16(CTX组)随机对照治疗晚期肺腺癌患者61例,其中IFO组32例,CTX组29例。治疗结束后4周评价疗效。结果IFO组近期有效率为31.3%(10/32),CTX组为24.1%(7/29),两组比较差异无显著性(P>0.05)。IFO组中位生存期7.5个月(2～24个月),CTX组7.0个月(1～18个月)。IFO组镜下血尿发生率为12.5%(4/32),CTX组为0(P<0.05)。其他毒性相似(P>0.05)。结论ICE和CCE方案对晚期肺腺癌均有较好的疗效,且IFO对晚期肺腺癌的疗效较CTX为优。
Objective To compare the therapeutic effectiveness and toxicity of ICE and CCE regimens in treatment of advanced lung adenocarcinoma.Methods From May 1999 to May 2004, comparison of 61 advanced lung adenocarcinoma treated with ICE and CCE regimens was carried out.ICE(ifosfamide,carboplatin,etoposide) group included 32 patients and CCE(cyclophosphamide,carboplatin,etoposide) group 29 patients.The response rates and toxicity were compared using the χ2 test.Results The overall response rate was 31.3%(10/32) in ICE group and 24.1% (7/29) in CCE group (P>0.05).By the end of July 2004,the median survival time in ICE group and CCE group were 7.5(2-24)months and 7.0(1-18) months respectively.The bloody urine rate was ~12.5% (4/32) in ICE group and 0(0/29) in CCE group(P<0.05).Conclusion Ifosfamide and cyclophosphamide were effective anti-cancer drugs for advanced lung adenocarcinoma.ICE regimen was as effective as CCE regimen for advanced lung adenocarcinoma.
出处
《中国肿瘤临床与康复》
2005年第3期221-223,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
